Endophenotype Characterization of a Family Psychiatric Disorder

Endophenotype Characterization of a Family Psychiatric Disorder of the Bipolar Spectrum, With an Autosomal Dominant Expression

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02843997

Acronym

EnBiGen

Enrollment

Registered

2016-07-26

Start date

2015-02-28

Completion date

2018-02-28

Last updated

2016-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Keywords

Bipolar disorder, Endophenotype, Family, Autosomal dominant expression, Sequencing, Heritability

Brief summary

Bipolar disorder is a chronic and frequent mood pathology, that impacts on emotional and socio-professional life of sick subjects, and also increase mortality by suicide. Suicide is considered as a bipolar disorder result. The main goal of this study is the endophenotype characterization from a clinical and cognitive point of view, of a bipolar spectrum's disorder present in a family, and then highlight a mutation of one of the genes involved is this disorder.

Detailed description

Heritability of bipolar disorder is now well established, but seems to be multifactorial in most of the cases. The use of an endophenotype characterized in a family presenting numerous bipolar sufferers enable to reflect the expression of simpler genetic variants than those involved in the disease, and might enable the identification of genes involved in the etiopathogenesis of this endophenotype.

Interventions

GENETICEndophenotype and sequencing

Draw an endophenotype and genetic study

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Members of a family adult (more than 18 years) * Signed informed consents * Registered to a French social security or possesor of the European Health Insurance Card

Exclusion criteria

Clinical part : * Refusal to sign the participation study consent. * Organic affection likely to affect cognitive abilities and brain structures or acute decompensation of a bipolar disorder. Genetic part : * Refusal to sign the genetic sample consent.

Design outcomes

Primary

Measure	Time frame	Description
Neuropsychological evaluations tests	One day	Neuropsychological evaluations (about one hour) : TMT (Trail Making Test) A and B, Stroop VFT (Visual Field Testing), DST (Dyslexia Screening Test) Tower of London test Hayling, CPT (continuous performance task) CVLT (California Verbal Learning Test) tests.
Eye tracking.	One hour	The volunteer will follow an instruction according to the color seen on a screen. This instruction is to look at the side where there is a flashlight and to look at the opopsite if the light is unbroken. Mistakes will be count.
Blood sampling	3 minutes	Genetic sample for extraction of DNA.

Countries

France

Contacts

Primary ContactJérôme Holtzmann, Doctor

jholtzmann@chu-grenoble.fr04 76 76 54 14

Backup ContactJohn Rendu, Doctor

jrendu@chu-grenoble.fr04 76 76 55 73

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026